Goldenwell Biotech (GWLL) EBIAT (2019 - 2025)
Goldenwell Biotech (GWLL) has disclosed EBIAT for 7 consecutive years, with -$7984.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, EBIAT rose 65.38% year-over-year to -$7984.0, compared with a TTM value of -$75117.0 through Sep 2025, up 39.83%, and an annual FY2024 reading of -$131498.0, down 12.05% over the prior year.
- EBIAT was -$7984.0 for Q3 2025 at Goldenwell Biotech, down from -$5220.0 in the prior quarter.
- Across five years, EBIAT topped out at -$4584.0 in Q3 2022 and bottomed at -$920332.0 in Q4 2022.
- Average EBIAT over 5 years is -$73585.8, with a median of -$27536.0 recorded in 2024.
- The sharpest move saw EBIAT plummeted 16053.42% in 2021, then soared 97.74% in 2023.
- Year by year, EBIAT stood at -$29541.0 in 2021, then tumbled by 3015.44% to -$920332.0 in 2022, then skyrocketed by 97.74% to -$20799.0 in 2023, then crashed by 32.39% to -$27536.0 in 2024, then soared by 71.01% to -$7984.0 in 2025.
- Business Quant data shows EBIAT for GWLL at -$7984.0 in Q3 2025, -$5220.0 in Q2 2025, and -$34377.0 in Q1 2025.